Meta AnalysisID 1816
关于1-磷酸鞘氨醇调节剂在炎症性肠病和其他免疫介导疾病中安全性的系统评价（不含Meta分析）方案
CRD42020172575
What is the safety profile of sphingosine 1 phosphate modulators in patients with immune-mediated disorders?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 1816
- Evidence Id
- 10374
- Core Evidence Id
- 10374
- Source Meta Analysis Id
- 1761
- Herb2 Meta Analysis Id
- HBMA001761
- Crd Id
- CRD42020172575
- Title
- Protocol for a systematic review without meta-analysis of the safety of sphingosine 1 phosphate modulators in inflammatory bowel disease and other immune-mediated diseases
- Review Question
- What is the safety profile of sphingosine 1 phosphate modulators in patients with immune-mediated disorders?
- Study Type Included
- controlled studies or observational studies (cohort studies)
- Condition Being Studied
- Inflammatory bowel disease (Crohn's disease and ulcerative colitis), multiple sclerosis and chronic psoriasis
- Participant
- Adult patients with inflammatory bowel disease, multiple sclerosis or chronic psoriasis
- Animal
- Human Disease Modelled
- Intervention
- Administration of one of the following sphingosine 1 phosphate modulators: fingolimod, ozanimod, posanimod, siponimod, etrasimod, amiselimod
- Comparator Control
- Patients with same conditions exposed to placebo and/or other active interventions (immunomodulators)
- Main Outcome
- Incidence rates of adverse events and serious adverse events Measures of effect Incidence rates measured in 1000 cases-person/year
- Outcome Measure
- Additional Outcome
- Incidence rates of adverse events of special interest: serious infections, malignancy, cardiac and ocular adverse events, herpes zoster infection, progressive multifocal leukoencephalopathy Measures of effect Incidence rates measured in 1000 cases-person/year
- Study Method
- Epidemiologic, Systematic review
- Keyword
- Fingolimod Hydrochloride; Humans; Inflammatory Bowel Diseases; Phosphates; Receptors, Lysosphingolipid; Sphingosine
- Contact
- Organisational Affiliation
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Review Stage
- First Submission Date
- Registration Date
- Anticipated Start Date
- Anticipated Completion Date
- Title Cn
- 关于1-磷酸鞘氨醇调节剂在炎症性肠病和其他免疫介导疾病中安全性的系统评价（不含Meta分析）方案
- Title En
- Protocol for a systematic review without meta-analysis of the safety of sphingosine 1 phosphate modulators in inflammatory bowel disease and other immune-mediated diseases
- Bilingual Status
- complete